Wedbush analyst Liana Moussatos maintained a Buy rating on Global Blood Therapeutics (NASDAQ: GBT) today and set a price target of $73. The company’s shares closed on Friday at $46.55.
According to TipRanks.com, Moussatos is a 3-star analyst with an average return of 2.8% and a 43.2% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Catabasis Pharmaceuticals, and Kala Pharmaceuticals Inc.
Currently, the analyst consensus on Global Blood Therapeutics is a Strong Buy with an average price target of $83.44, implying a 79.2% upside from current levels. In a report issued on July 25, William Blair also assigned a Buy rating to the stock.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $68.05 and a one-year low of $26.10. Currently, Global Blood Therapeutics has an average volume of 1.31M.
Based on the recent corporate insider activity of 51 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases.
Read More on GBT:
